Table 2.

Associations of serum lycopene concentration with the risk of total, low-, and high-grade prostate cancer. PCPT, 1994 to 2003

Odds Ratio (95% CI)a
Lycopene (μg/dL)
Q1Q2Q3Q4Continuous perP
(<26.3)b(26.3 to <36.0)b(36.0-<46.6)b(≥46.6)bPtrend10 μg/dL
Placebo
 Gleason 2–61.000.85 (0.64,1.13)1.02 (0.77,1.34)0.99 (0.74,1.32)0.731.01 (0.94,1.08)0.80
N (cases/controls)173/252162/250199/258201/248735/1,008
 Gleason 7–101.001.09 (0.71,1.67)0.83 (0.53,1.32)1.16 (0.74,1.81)0.791.01 (0.91,1.12)0.91
N (cases/controls)50/25256/25042/25856/248204/1,008
 Gleason 8–101.000.60 (0.22,1.59)1.15 (0.50,2.69)1.31 (0.56,3.08)0.291.04 (0.85,1.27)0.68
N (cases/controls)11/2527/25013/25814/24845/1,008
Finasteride
 Gleason 2–61.000.77 (0.54,1.09)0.80 (0.56,1.15)0.80 (0.56,1.15)0.280.96 (0.88,1.04)0.31
N (cases/controls)115/185102/18997/179108/190422/743
 Gleason 7–101.001.27 (0.84,1.91)1.01 (0.65,1.57)1.13 (0.73,1.75)0.891.01 (0.92,1.11)0.85
N (cases/controls)57/18578/18956/17966/190257/743
 Gleason 8–101.001.19 (0.63,2.24)0.68 (0.32,1.43)1.11 (0.56,2.2)0.871.01 (0.86,1.18)0.94
N (cases/controls)20/18525/18913/17922/19080/743
Total
 Gleason 2–61.000.82 (0.66,1.02)0.93 (0.74,1.16)0.91 (0.72,1.14)0.730.99 (0.94,1.04)0.66
N (cases/controls)288/437264/439296/437309/4381,157/1,751
 Gleason 7–101.001.19 (0.89,1.60)0.93 (0.68,1.28)1.16 (0.85,1.58)0.801.01 (0.94,1.08)0.79
N (cases/controls)107/437134/43998/437122/438461/1,751
 Gleason 8–101.000.99 (0.59,1.66)0.87 (0.50,1.51)1.20 (0.71,2.04)0.651.02 (0.9,1.15)0.77
N (cases/controls)31/43732/43926/43736/438125/1,751

aControlled for age, race, diabetes, serum cholesterol, and BMI; models for total sample controlled in addition for treatment arm.

bQuartiles were calculated using distribution among controls.